Introduction
Atrial fibrillation (AF) portends an increased risk of ischaemic stroke with significant morbidity and mortality. 1 Current guidelines support identifying patients with AF who may benefit from anticoagulant therapy in stroke prevention. However, it is recommended that the initiation of antithrombotic therapy be individualized to account for bleeding risk. 2 Because those at high risk of stroke are also at risk of bleeding, 3 the clinical decision-making process surrounding initiation of treatment poses a significant challenge. This conundrum has contributed to the underutilization of anticoagulation. 4 The nonvitamin K oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban are at least as effective as vitamin K antagonists (VKAs) in preventing ischaemic stroke, are easier to use and have a favourable bleeding profile compared with warfarin, 5 although they are associated with higher cost. 6 Importantly, their availability has increased the complexity of an already complicated decision-making process in anticoagulation treatment.
There are several well established risk stratification schemes to predict adverse events in AF patients. The stroke risk scores and bleeding risk scores are useful in the identification of patients who warrant anticoagulation initiation and careful monitoring, no scores have been developed to predict a composite outcome of serious adverse events as a consequence of therapy. Further, no score exists that can help to guide the decision regarding which anticoagulant option offers better therapeutic benefit for an individual patient.
The Effective Anticoagulation with Factor Xa Next Generation in AF-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) was a three-arm, double-blind, double-dummy randomized clinical trial comparing two dose regimens of edoxaban with warfarin in 21 105 patients with AF and a CHADS 2 score > _ 2 at moderate-high risk of stroke. 17 Non-inferiority was met for higher-and lower-dose edoxaban regimens (HDER and LDER) for stroke or SEE, and both arms demonstrated a significant reduction in major bleeding. 18 The goals of the present analysis were two-fold. First, utilizing the ENGAGE AF-TIMI 48 population, we derive a novel integer score predictive of a serious net clinical outcome, consisting of disabling stroke, life-threatening bleeding, or all-cause mortality in patients receiving warfarin therapy. Second, in an effort to assist in deciding between NOAC and VKA treatment in anticoagulation-naive patients, we test the hypothesis that the utilization of this score may identify specific patients who have a differential response to therapies.
Methods

Study population and derivation cohort
We utilized the VKA naïve patients from the warfarin arm of the ENGAGE AF-TIMI 48 trial intention-to-treat population to derive the score for the NCO. The trial design has been published previously. [17] [18] Patients with AF and a CHADS 2 score > _ 2 were randomized in a 1:1:1 ratio to HDER, LDER, or warfarin. Patients with a body weight < _ 60 kg, receiving a concomitant potent P-glycoprotein (P-gp) inhibitor or who had a creatinine clearance (CrCl) 30-50 mL/min received a 50% reduction in the edoxaban dose. The International Normalized Ratio (INR) was measured at least monthly with the use of an encrypted point-of-care device. Major exclusion criteria included CrCl < 30 mL/min, a reversible cause for AF, dual antiplatelet therapy, acute coronary syndromes or stroke within 30 days, mitral stenosis, or mechanical valves. 17 The VKA naïve patients, defined as having been on treatment < _ 60 consecutive days prior to enrollment, were selected from the warfarin arm for the derivation cohort. The analysis was then applied to the 5532 VKA naïve patients from both HDER and LDER arms. Rationale for utilization of VKA naïve patients in the derivation cohort reflects both clinical equipoise in this population and the results from a previously published post-hoc analysis, which demonstrated a treatment interaction in pre-specified endpoints according to prior VKA experience. 19 
Endpoint definitions and adjudication
The primary efficacy and safety endpoints of the ENGAGE AF-TIMI 48 trial were the composite of ischaemic or haemorrhagic stroke or SEE, and major bleeding. Pre-specified net clinical outcomes were as follows: primary -stroke, SEE, major bleeding or death; secondary-disabling stroke, life-threatening bleeding, or death. 17 In the present analysis, the pre-specified secondary net clinical outcome, herein referred to as the NCO, was the chosen endpoint of interest in the derivation of the integer score since it captures those events most specific for highest severity and irreversibility. All endpoints were adjudicated by an independent committee, which was blinded to study treatment. ENGAGE AF-TIMI 48 was supported by a grant from Daiichi Sankyo (NJ). The TIMI study group co-ordinated the trial, developed this analysis and performed all statistical tests independent of the sponsor. Written informed consent was obtained from all patients. The trial was approved by multinational site institutional review boards and conducted according to principles of the Declaration of Helsinki.
Statistical analysis
All analyses followed the intention-to-treat principle. Baseline characteristics in patients with and without the NCO are presented as median and interquartile ranges for continuous variables and percentages for categorical variables. To develop the risk prediction model, general principles from the TRIPOD statement were followed 20 and the flow of data inclusion is illustrated in Supplementary material online, Figure S1 . Cox proportional hazards modelling tested each baseline variable on the time-to-event of the first occurrence of the NCO. Candidate variables were tested for co-linearity by Spearman correlation matrices, which also identified interactionterms to be included in the model. To develop an integer score that could translate into a clinically useful model, spline function analyses were utilized to assess linearity of continuous variables and justify cut-points for categorization. Age was categorized as < _ 65 years (referent), 66-74 years, or > _ 75 years. Creatinine was categorized as < 110 (referent) or > _ 110 umol/L (1.25 mg/dL). Haemoglobin was categorized as > _ 13 (referent) or < 13 g/dl. Ejection fraction categories were pre-specified on the case report form and were defined as > _ 50% (referent), 30-49%, <30%, or unknown. An initial saturated Cox proportional hazards model was developed that forced all candidate variables and interaction terms into the model. An alpha level of 0.1 from the saturated model was used as a threshold to enter a variable predictor into a backwards elimination model. Beta-coefficients are presented for the final Cox regression model, with significant associations reported as hazard ratios (HRs) with 95% confidence intervals (CIs). C-statistics and 95% CI by the jack-knife method were estimated to quantify the discriminatory performance of the regression models. A bootstrap method of validation utilizing 1000 replications was applied to the final model. Calibration was assessed by the Gronnesby and Borgan method comparing observed and predicted events to assess goodness of fit. 21 To translate the final model into a risk prediction score, the HR for each predictor variable was rounded to its closest integer to develop score weights. Annualized Kaplan-Meier event rates using persontime of follow up were calculated according to an incremental increase in integer score and then categorized into three categories: low (0-6 points), intermediate (7-9 points) , and high (> _ 10 points) risk. Three-year Kaplan-Meier curves were then generated according to the three risk categories.
To assess a differential therapeutic benefit, the integer risk score categories were applied to the VKA naïve population randomized to HDER (n = 2768) and LDER (n = 2764). Kaplan-Meier event rates were then calculated in the edoxaban arms, and treatment interaction assessed by calculating HR and 95% CI of the NCO in the HDER and LDER compared with warfarin. In sensitivity analyses, the model was applied to the VKA-experienced cohort. In addition, treatmentinteractions by score category were assessed for additional prespecified endpoints. Lastly, discrimination of established risk scores for stroke, major bleeding, and TTR prediction was assessed for the NCO. Data were analysed utilizing SAS Version 9.4 (SAS Institute, Inc., Cary, North Carolina) and R Software Version 3.1.3.
Results
Patient characteristics and risk factors for net clinical outcome
The previously published study population of ENGAGE AF-TIMI 48 consisted of 21 105 patients with a median age of 72 years and a mean CHADS 2 score of 2.8. Follow-up data were available for 99.5% of patients. Vitamin K antagonist naïve patients constituted 41.2% of the population. 18 Baseline characteristics for the derivation cohort of VKA naive patients in the warfarin arm are presented ( Table 1) . Median TTR was 64.6% and 22% of patients had a CHADS 2 score > 3. Of 2898 patients in the derivation cohort, 457 NCO events occurred over median follow-up of 2.7 years and a total person-time of 7549.5 years (6.05%/year) (Supplementary material online, Figure S1 ). The risk predictors associated with time-to-event of the NCO and weighted points from the stepwise backwards selection Cox regression model are shown ( Table 2) . The integer risk score, herein called TIMI-AF score, had a maximum of 17 points. Discriminatory function as measured by the area under the curve (AUC) and C-statistic for the final selection model was 0.693. The model was validated internally by bootstrap with a C-statistic of 0.683, and calibration was assessed with the Gronnesby and Borgan test (P = 0.62).
Integer score distribution and incidence of serious net clinical outcome in the vitamin K antagonist naive warfarin group After exclusion of 106 patients with missing data from the derivation cohort, risk scores were calculated for 2 792 patients, which included a total of 439 events and 7272.7 patient-years of follow-up (Supplementary material online, Figure S1 ). Integer scores, which ranged from 0 to 14, demonstrated annualized event rates of the net clinical outcome of 1.44%/year and 34.06%/year for the lowest (0-2 points) and highest scores ( 12 points), respectively ( Table 3) . Patients in the 'low-risk' group experienced 174 events (3.53%/year), in the 'intermediate-risk' group 203 events (9.91%/year), and in the 'highrisk' group 62 events (20.81%/year) ( Table 4) . The Kaplan-Meier curves for the NCO according to risk score category and treatment arm are displayed in Figure 1 . The KM event rates (log-rank P < 0.001) diverged within 6 months and continued through the end of follow-up.
Performance of risk score in edoxaban arms
Of the 2768 and 2764 VKA naive patients randomized to HDER or LDER, the NCO occurred in 354 (12.8%) and 356 (12.9%) patients, respectively. In the evaluation of the risk-prediction score on the NCO in the edoxaban arms, compared with the warfarin arm, the percent distributions were overall similar (Supplementary material online, Table S1 and Supplementary material online, Figure S2 ). For the low-, intermediate-and high-risk categories, annualized event rates in the edoxaban arm were 3.6%, 6.6%, and 12.8% in the HDER, and 3.6%, 6.8%, and 12.8% in the LDER, respectively.
When compared with warfarin, there was a significant treatment interaction between risk score categories for both HDER and LDER arms (global P-value for interaction 0.008 and 0.014, respectively), with significantly lower event rates of the NCO in the intermediate and high risk seen with both HDER and LDER arms (Figure 2) . Within the high-risk score category, a 39% decrease in risk was demonstrated for the NCO in the HDER arm compared with warfarin (HR 0.61; 95% CI 0.41-0.91; P = 0.015). Similar results were seen with LDER (HR 0.61; 95% CI 0.40-0.92; P = 0.02). In the low-risk category, the event rates for the NCO were similar between the three treatment arms (HR 1.01; 95% CI 0.82-1.24 and HR 1.01; 95% 0.82- 1.25 for HDER and LDER vs. warfarin, respectively). The estimated 3-year relationship of a relative treatment effect of pooled edoxaban compared with warfarin in VKA naive patients is shown in Figure 3 .
Sensitivity analyses
Application of the prediction model to the VKA experienced patients for the NCO yielded a lower C-statistic of 0.64, demonstrating a loss of discrimination for these patients, as was hypothesized. The overall treatment interaction with the risk-score category and NCO by treatment arm was no longer present (global P-value for interaction for HDER and LDER compared with warfarin 0.93 and 0.53, respectively). For HDER and LDER (N = 8039) compared to warfarin (N = 4007), risk of the NCO was similar in the three risk categories (Supplementary material online, Figure S3) .
The model was then tested for a treatment interaction according to risk-score category in the additional pre-specified endpoints from ENGAGE AF-TIMI 48, which included all-cause mortality, cardiovascular mortality, and other pre-specified composite outcomes (Supplementary material online, Figure S4 ). These analyses demonstrated similar differential treatment results as was the case for the NCO. Benefit was demonstrated in the HDER and LDER compared with warfarin in the intermediate-and high-risk categories, with no significant difference by treatment in the low-risk.
Last, annualized event rates and C-statistics for the well-established risk stratification schema were calculated for the prediction of the NCO in VKA naïve patients in the warfarin arm, and are presented in Supplementary material online, Table S2 . The C-statistics for these scores in the derivation cohort ranged from 0.59 to 0.64.
Discussion
The TIMI-AF score predicted a serious net outcome associated with warfarin therapy in AF patients who are VKA naïve, and identified high risk patients who had a favourable treatment benefit with edoxaban compared with warfarin. Derived from a cohort of patients from ENGAGE AF-TIMI 48 for whom the need for anticoagulation was established based on the CHADS 2 score, the proposed risk model to predict a clinically relevant outcome of disabling stroke,
life-threatening bleeding, or all-cause mortality demonstrated good discriminatory power.
Given their many favourable characteristics, use of NOACs in AF has been increasing in clinical practice since their approval. 22 As clinicians are presented with increased treatment options, this precisionbased risk prediction analysis aimed to identify those patients who would benefit more from a NOAC. Anticoagulant naïve patients were selected for the derivation cohort since in this group there exists clinical equipoise in regards to initiation of therapy with warfarin or a NOAC based on a composite of baseline factors. Vitamin K antagonist naïve patients often experience unpredictable adverse events after warfarin initiation resulting in early termination of therapy due to safety concerns. A large multicentre cohort study of 40 449 patients with mean CHADS 2 and CHA 2 DS 2 VASc scores of 2.1 and 3.3, respectively, demonstrated that patients who achieved a TTR >70% had significantly fewer complications on warfarin therapy compared with those with TTR < 70%. 23 The SAMe-TT 2 R 2 has been validated in prior studies to assist in the prediction of poor INR control of < 60%, which could therefore assist clinicians in the selection of anticoagulant. 16, 24 We sought to define those clinical factors beyond TTR predictive of adverse outcomes. In the present analysis, the derivation cohort excluded VKA experienced patients who are more likely to be on a stable regimen. In a sensitivity analysis, the risk score for the NCO had relatively poor predictive performance in these VKA experienced patients and no treatment interaction was demonstrated. Independent predictors of the NCO were older age, male sex, non-white race, systolic dysfunction, kidney dysfunction, AF or atrial flutter on baseline ECG, and a history of prior ischaemic stroke, carotid artery disease, myocardial infarction, diabetes mellitus, and anaemia. Several of these factors have been previously demonstrated to be independent risk factors for stroke or major bleeding, especially older age and renal dysfunction. [7] [8] [9] [10] [11] [12] [13] [14] [15] Baseline AF or AFL rhythm was predictive of the NCO, a probable reflection of patients in sustained or permanent AF and longer history of the arrhythmia. These findings are consistent with those from the AMADEUS trial, which reported that anticoagulated patients with permanent AF had a 68% increased risk of cardiovascular death, stroke or systemic embolism relative to those with non-permanent AF. 25 . Existing scores have been designed to assist in the decision of initiating anticoagulation based on stroke risk while addressing potential reversible factors that may increase bleeding risk and their use should continue in this manner. They were not derived to predict a net clinical outcome or to identify patients with a therapeutic benefit from NOACs compared with VKAs. The TIMI-AF score is the first risk stratification scheme in AF that enables optimization of patient outcomes by identifying specific patients who have markedly improved outcomes with a NOAC compared with warfarin. In addition, it identifies low risk patients for whom the selection of a particular anticoagulant may not contribute to adverse outcomes. Given the relatively high cost of NOACs and inaccessibility of these drugs for some patient populations, this score can therefore help determine specific patient groups who will be at low risk on warfarin. We believe this risk score could enhance anticoagulation prescription practices utilizing a personalized medicine approach. A recommended algorithm for clinical use based on this analysis is illustrated (Figure 4) . 
Limitations
ENGAGE AF-TIMI 48 was a registration pathway trial and therefore was purposely enriched for higher risk individuals with a CHADS 2 score of at least 2. Nearly 22% of patients in the VKA naïve population utilized in this analysis had a CHADS 2 score > 3. Therefore, the ability for this risk score to predict a differential therapeutic benefit between a NOAC and VKA in patients with low (0-1 points) CHADS 2 scores is unknown. In addition, since the TIMI-AF score was derived and internally validated from a single population on VKA, overfitting is a potential limitation and external validation is needed to evaluate the model's performance beyond the derivation cohort.
This analysis was limited to patients who benefit from either edoxaban or VKA, and therefore application of the TIMI-AF risk score to the other NOACs from trial populations of varying baseline stroke and bleeding risk warrants ongoing study. The selection of the derivation cohort for this score was based on the known treatment interaction with edoxaban and VKA experience. This treatment interaction was not evident in other NOAC trials, although there was an insignificant trend of increased efficacy with rivaroxaban in VKA naive patients. [26] [27] [28] The VKA naïve patients constituted a minority of AF patients in the ENGAGE AF-TIMI 48 trial (41%) in which a history of AF was an inclusion criterion. However, going forward an increasing proportion of patients presenting to the medical care system will be oral anticoagulant naïve, making them suitable for the application of this risk score.
Conclusion
We developed the TIMI-AF score that predicts a serious net clinical outcome in VKA naïve patients treated with warfarin for stroke prevention in AF and identified patient groups for whom a differential therapeutic response exists. Edoxaban demonstrated improved outcomes for those with intermediate-or high-risk scores, whereas warfarin performed as well as edoxaban with low-risk scores. In VKA experienced patients, there was no difference in outcomes across risk score categories by treatment arm. Utilization of this prediction score in anticoagulant naïve patients may improve risk prediction of an important net clinical outcome inclusive of disabling stroke, life- 
